Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

Patients with advanced stage non–small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first‐line treatment had better progression‐free survival, overall response rate and qu...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2018-02, Vol.14 (1), p.23-31
Main Authors: Aw, Derrick Chen‐Wee, Tan, Eng Huat, Chin, Tan Min, Lim, Hong Liang, Lee, Haur Yueh, Soo, Ross A.
Format: Article
Language:English
Subjects:
adverse drug events
Chemotherapy
Diarrhea
Enzyme inhibitors
Epidermal growth factor
Epidermal growth factor receptors
Exanthema
gastrointestinal tract
Gefitinib
Mutation
mutations
Non-small cell lung carcinoma
non–small cell lung cancer
Protein-tyrosine kinase receptors
Quality of life
Skin
Stomatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with advanced stage non–small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations using EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib and afatinib as first‐line treatment had better progression‐free survival, overall response rate and quality of life than those on chemotherapy. Although EGFR TKIs are commonly associated with skin‐related (rash, xerosis and paronychia) and gastrointestinal‐related (diarrhea and stomatitis) adverse events (AEs), these effects are usually mild. But severe cases can occur, significantly affecting patient's well‐being, treatment compliance and quality of life. Therefore, patient education, early diagnosis, and prophylactic treatment are important strategies to optimally manage EGFR TKI‐related adverse effects. In this review, we summarize the commonly encountered EGFR TKI‐related AEs and provide a current overview of AE management in local practice with a focus on Asian patients.
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.12687